| | |
C.H. Unnikrishnan 11:04 PM | October 28,2009
The US drug regulator earlier this year seized all inventories at Caraco’s Michigan plant after it failed to comply with manufacturing quality norms
|
|
Bloomberg 12:06 AM | August 19,2009
The decision has no bearing on Lilly’s compound patent for Gemzar, Lilly said
|
|
C.H. Unnikrishnan 10:13 PM | July 30,2009
Israeli drug maker Taro Pharmaceutical which was dragged to an Israeli court by majority owner Sun Pharmaceutical for not disclosing financial details with shareholders, has decided to conduct a shareholder meeting
|
|
C.H. Unnikrishnan and Radhieka Pandeya 12:34 AM | April 20,2009
Average growth in sales for the quarter likely to be less than 11%, compared with 14% in the year-ago period
|
|
01:15 AM | January 30,2009
Pune-based intellectual property rights consultant Ganesh Hingmire has filed the application with the GI Registry in Chennai on behalf of about 1,300 farmers
|
|
PTI 04:34 PM | January 08,2009
Sun had rejected Taro’s offer of conducting a shareholder referendum at any price of its (Sun’s) choosing to settle the issue, besides offering other options
|
|
Radhieka Pandeya and Lison Joseph 12:31 AM | November 25,2008
India’s drug regulator has cancelled licences granted to 17 companies to produce anti-obesity drug rimonabant
|
|
Lison Joseph 12:19 AM | October 17,2008
Dr Reddy’s was the first Indian drug company to hive off its drug discovery related research and development activities into a separate firm
|
|
Saikat Chatterjee / Bloomberg 12:14 AM | August 28,2008
Sun Pharmaceutical in May 2007 offered to buy Taro for $230 million (Rs1,005 crore) in cash and an additional $224 million to refinance debt
|
|
01:46 PM | August 27,2008
Court also ordered Taro and other plaintiffs to pay Sun Pharma’s costs related to the litigation
|
|
03:59 PM | March 11,2008
Indiareit currently manages about $450 million raised through two series of funds in the domestic market and one in the overseas market
|
|
Mark to Market | Manas Chakravarty and Mobis Philipose 11:30 PM | March 03,2008
The Budget proposals hardly provide any reason for pharma shares to outperform the market by around 7%
|
|